Author

Evangelia Kokalaki

Observed names: E. Kokalaki, EK Kokalaki, Evangelia K Kokalaki, Evangelia K. Kokalaki, Kokalaki, E

Institution: Autolus (United Kingdom)

Observed institutions: Autolus (United Kingdom), University College London

ORCID: 0000-0003-4686-6806

Observed ORCID: 0000-0003-4686-6806

OpenAlex ID: A5048985687

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy

2014 · Brian Philip, Evangelia Kokalaki, et al. · Blood · 410

Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma

2020 · Karin Straathof, Barry Flutter, et al. · Science Translational Medicine · 205

PDF

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL

2023 · Sara Ghorashian, Giovanna Lucchini, et al. · Blood · 100

PDF

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR

2023 · Evangelia Kokalaki, Biao Ma, et al. · Molecular Therapy · 44

PDF

Tunable control of CAR T cell activity through tetracycline mediated disruption of protein–protein interaction

2021 · Alastair Hotblack, Evangelia K. Kokalaki, et al. · Scientific Reports · 29

PDF

Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies

2024 · Mathieu Ferrari, Matteo Righi, et al. · Nature Communications · 26

PDF

Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors

2023 · Matteo Righi, Isaac Gannon, et al. · Cancer Immunology Research · 15

PDF

Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2

2023 · Julia Taylor, Anna Bulek, et al. · Frontiers in Immunology · 9

PDF

A Dominant Negative SHP-2 Which Abrogates PD-1 Signalling Pathways and Restores Function of Cytotoxic CAR T Cells

2017 · Vania Baldan, Priyanka Ghongane, et al. · Blood · 5

Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL

2022 · Sara Ghorashian, Giovanna Lucchini, et al. · Blood · 4

An APRIL Based Chimeric Antigen Receptor to Simultaneously Target BCMA and TACI in Multiple Myeloma (MM) Has Potent Activity in Vitro and in Vivo

2016 · Lydia Sarah Hui Lee, Benjamin Owen Draper, et al. · Blood · 3

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR

2023 · Evangelia Kokalaki, Biao Ma, et al. · Molecular Therapy · 2

A Dual Targeting Car‐t Cell Approach for the Treatment of B Cell Malignancies

2017 · S. Thomas, V. Baldan, et al. · Hematological Oncology · 2

PDF

Antibody format matters: A comparative analysis of VHH and scFv domains reveals superior in vivo CAR T cell function with VHH domains

2026 · Alexander Kinna, Preeta Datta, et al. · Molecular Therapy · 1

S259: Dual Antigen Targeting With Co-transduced Cd19/22 Car T Cells for Relapsed/refractory All

2022 · S. Ghorashian, G. Lucchini, et al. · HemaSphere · 1

Generation of a Highly Sensitive CD22 CAR

2019 · Evangelia K Kokalaki, Biao Ma, et al. · Blood · 1

Supplementary Table 1 from Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors

2025 · Matteo Righi, Isaac Gannon, et al.

PDF

Supplementary Table 2 from Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors

2025 · Matteo Righi, Isaac Gannon, et al.

PDF

Supplementary Figure S1-S26 from Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors

2025 · Matteo Righi, Isaac Gannon, et al.

PDF

Data from Enhancing CAR T-cell therapy using Fab-Based Constitutively Heterodimeric Cytokine Receptors